Expand All | Collapse All
Robert D. Siegel, MD, Chair
Dr. Siegel, a board certified internist, hematologist and medical oncologist, is the Oncology Program Director for the Bon Secours St. Francis Health System in Greenville, South Carolina. Prior to his appointment to program leadership at St. Francis, Dr. Siegel had been a community-based oncologist with particular interest in quality improvement initiatives and cancer care delivery research.
Dr. Siegel has served the American Board of Internal Medicine (ABIM) as a member of the Medical Oncology Exam Writing Committee and is currently chair of its Medical Oncology Board. Additionally, he is a member of the ABIM Board of Directors and the ABIM Council. He has previously served as the co-Chair of the Quality of Care Subcommittee for the National Cancer Institute's Community Cancer Centers Program and is currently on the Executive Committee for Southeast Consortium for Oncology Research.
Dr. Siegel earned his medical degree at the Columbia University College of Physicians and Surgeons in New York. He completed his internship and residency training at the Barnes Hospital/Washington University School of Medicine in St. Louis; fellowship training in medical oncology and hematology at the Dana-Farber Cancer Institute in Boston; clinical fellowship in medicine at the Harvard Medical School in Boston; and fellowship training in hematology at Brigham and Women's Hospital.
As of April 2017, Dr. Siegel reported the following external relationships:
Funding for clinical trial expenses and staff, paid to Bon Secours St. Francis Hospital, from the following companies:
- Bristol-Myers Squibb, for a lung cancer clinical trial, kidney cancer clinical trial, and for a non-Hodgkin lymphoma clinical trial.
- Cancer Insight, for a melanoma clinical trial.
- Celgene, for two lymphoma clinical trials.
- ImmunoGen, Phase II study of the efficacy and tolerability of IMGN529 in combination with rituximab in patients with relapsed and/or refractory diffuse large B-cell lymphomas and other non-Hodgin's lymphomas.
- Merck, for clinical trials for head and neck carcinoma, colorectal carcinoma, breast carcinoma, lymphoma, and two stomach cancer clinical trials.
- Mirati Therapeutics, for a clinical trial for solid tumors.
- Onyx, for a multiple myeloma clinical trial.
- Pharmatech, for a metastatic colon cancer clinical trial.
- ProNAi, for a lymphoma clinical trial.
- TG Therapeutics, for a chronic lymphocytic leukemia clinical trial.
- Biodesix, for an observational study assessing the clinical effectiveness of validating immunotherapy tests in subject with non-small cell lung cancer.
- CerRX Inc., for a Phase II trial of intravenous fenretinide emulsion for patients with relapsed/refractory peripheral T-cell lymphomas.
- Boston Biomedical, for a Phase II trial of metastatic pancreatic ductal adenocarcinoma.
- GRAIL, Inc., for a trial of use deep sequencing of circulating cell-free nucleic acids to develop assays to detect cancer early in blood.
Dr. Siegel serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- American Society for Clinical Oncology, Chair of Quality Oncology Practice Initiative Certification Oversight Committee, Member of Maintenance of Certification Task Force, receiving reimbursement for travel expenses.
- Dr. Siegel also serves on the Advisory Committee for Wellpoint Oncology Clinical Pathways Development, receiving reimbursement for travel expenses and honoraria for his service.
Tareq Al Baghdadi, MD
Dr. Al Baghdadi is a practicing board certified hematologist and medical oncologist at IHA Hematology and Oncology Associates in Ypsilanti, Michigan. He is also affiliated with St. Joseph Mercy Ann Arbor in Ann Arbor, Michigan.
Dr. Al Baghdadi has clinical interest in hematology, and breast and urologic cancers. He is a member of the American Board of Internal Medicine Medical Oncology Board, the National Cancer Institute Leukemia Steering Committee and the National Myelodysplastic Syndromes Study Steering Committee. Dr. Al Baghdadi also serves as co-Principal Investigator for the Michigan Cancer Research Consortium and is a member of the Alliance Community Oncology Leadership Committee.
He received his medical degree from the University of Damascus Faculty of Medicine in Syria. He completed residency training at William Beaumont Hospital in Royal Oak, Michigan, and fellowship training in hematology and oncology at Indiana University in Indianapolis, Indiana.
As of July 2017, Dr. Al Baghdadi reported the following external relationships:
Dr. Al Baghdadi serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- Alliance for Clinical Trials in Oncology, Community Oncology Committee Member, receiving reimbursement for travel expenses, paid to the Integrated Healthcare Association.
- National Heart, Lung, and Blood Institute, National Myelodysplastic Syndromes Study Protocol Writing Committee Member, without compensation.
Ilene A. Galinsky, MSN
Ms. Galinsky is a Senior Program Research Nurse Practitioner in the Adult Leukemia Program at Dana-Farber Cancer Institute (DFCI) and Brigham and Women's Hospital (BWH) in Boston.
She has worked at DFCI for 26 years, beginning as a Selected Nurse Intern on the oncology inpatient service. After serving as Charge Nurse on the inpatient service and as a Program Nurse in Harvard's Joint Center for Radiation Therapy, she joined the DFCI/BWH Leukemia Program as a Program/Research Registered Nurse. After receiving a master's degree in Adult Primary Care in 2004, she became the Senior Mid-Level Practitioner in the Adult Leukemia Program overseeing many aspects of clinical research activities as well as participating in the care of many patients with leukemia and related disorders.
Currently, she serves as the co-Chair of the Alliance for Clinical Trials in Oncology's Oncology Nurse Committee, as well as nurse liaison to the Leukemia, Myeloma, and Transplant Alliance committees. She is a member of the American Society of Hematology and the Oncology Nursing Society and serves on the American Board of Internal Medicine Medical Oncology Board.
Ms. Galinsky earned her bachelor's and master's degrees in nursing from Northeastern University in Boston.
As of January 2017, Ms. Galinsky reported the following external relationships:
Clinical research, with funding for clinical trial expenses and clinical research staff, paid directly to Dana-Farber Cancer Institute, from the following companies:
- Arog Pharmaceuticals, for an acute myeloid leukemia induction trial.
- Kite Pharma, for a CART T-cell trial for acute lymphoid leukemia.
- Novartis, for relapsed amyotrophic lateral sclerosis trials.
Attendance at investigators' meetings, with compensation for travel expenses and honoraria from the following companies:
- Pfizer, for an Advisory Board for inotuzimab to prepare for FDA approval and development of educational material.
- Novartis, for an Education Panel for midastaurin.
Ms. Galinsky serves in a significant role with the following healthcare-related organization, receiving reimbursement for travel as listed:
- Alliance Cooperative Group, serving as the Vice Chair of the Nursing Oncology Board and serves as the Nurse Liaison to the Leukemia/Transplant and Myeloma Disease Programs, receiving reimbursement for travel expenses.
Robert G. Maki, MD, PhD
Dr. Maki, who is board certified in Internal Medicine and Medical Oncology, is a Professor in the Department of Medicine at Northwell-Hofstra Medical School and at Cold Spring Harbor Laboratory. He practices at Northwell's Monter Cancer Center in Lake Success, New York, on the border of New York City. His efforts are directed toward an increasingly integrative effort sarcoma biology and treatment of sarcomas and in developmental therapeutics. His group conducts Phase I clinical trials as well as other clinical trials in adults with sarcomas, and the group also conducts translational studies in sarcoma biology to identify the next possible targets for new drugs to treat sarcomas. He is also the Director of Translational Oncology at the Sarcoma Alliance for Research through Collaboration.
Dr. Maki has over 25 years of experience in the biology and clinical management of sarcomas of soft tissue and bone such as gastrointestinal stromal tumors, angiosarcoma and desmoid tumors in adults and adolescents. He continues to have diverse interest in angiogenesis, epigenetics, clinical trial design and new drug development for this diverse group of malignancies. He has mentored more than 25 fellows and medical and doctoral students and continues to develop collaborative clinical and translational studies on a national and international basis.
Dr. Maki currently serves as Chair of the American Board of Internal Medicine Medical Oncology Board Exam Committee, and as a member of the Medical Oncology Board.
After receiving his medical and doctoral degrees at Cornell Medical College in New York City, he was a resident at Brigham and Women's Hospital in Boston. He then completed a medical oncology fellowship at Dana-Farber Cancer Institute and was on staff at Dana-Farber before starting at Memorial Sloan-Kettering Cancer Institute in 1999. In 2011, he moved to the Mount Sinai Medical Center to develop the effort in adult sarcoma therapy and research. In 2016, he moved to Northwell's Monter Cancer Center.
As of January 2017, Dr. Maki reported the following external relationships:
Funding for clinical trial expenses and staff, paid to the Icahn School of Medicine at Mount Sinai Medical Center, from the following company:
- Eli Lilly and Company, providing funding for a trial of olaratumab in combination with three different regimens of cytotoxic chemotherapy for sarcomas.
- Immune Design, providing funding for a trial of NY-ESO-1 vaccine strategy with concurrent PD-L1 costimulator.
Attendance at investigators' meetings, with compensation as listed, from the following companies:
- Eli Lilly and Company, for clinical trials involving olaratumab, receiving reimbursement for travel expenses and honoraria.
- Immune Design, for trials in sarcoma, receiving reimbursement for travel expenses.
- TRACON Pharmaceuticals, related to a trial of an investigational antivascular agent in the treatment of sarcomas, receiving reimbursement for travel expenses.
Service on a data safety monitoring board for the following companies, with compensation for travel expenses and honoraria:
- AADi, for a nab-rapamycin Phase II study, receiving honoraria.
- Karyopharm, for a Phase III liposarcoma study of selinexor, receiving reimbursement for travel expenses and honoraria.
Service on a research-related expert panel or advisory board for the following company, with compensation for travel expenses and honoraria:
- Gem Pharmaceuticals, advising on novel anthracyclines in sarcoma studies, receiving honoraria.
Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with compensation for travel expenses and/or honoraria:
- Presage Biosciences, consulting regarding in vivo testing with small volume tissue samples as a multi-prong PDX model, receiving honoraria.
Work as an author or editor for the following company, with compensation as listed:
- UpToDate, receiving compensation as an author and editor.
Dr. Maki serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:
- American Joint Committee on Cancer, Committee co-Chair for Sarcoma Staging System V8, reworking sarcoma staging criteria for new edition of staging system, receiving reimbursement for travel expenses and honoraria.
- American Society of Clinical Oncology, serving as faculty at meetings and working on the cancer.net website, receiving reimbursement for travel expenses and honoraria.
- Sarcoma Alliance for Research through Collaboration, Translational Research Committee Chair, receiving reimbursement for travel expenses and honoraria, paid to Icahn School of Medicine at Mount Sinai Medical Center.
Suresh G. Nair, MD
Suresh Nair, MD, is the Physician-in-Chief of the Lehigh Valley Cancer Institute and leads the health network’s academic programs. Dr. Nair is the Medical Director of the Lehigh Valley Cancer Institute membership in the Memorial Sloan Kettering Cancer Center Alliance and has practiced oncology in the community setting for 27 years. He is the initial holder of The Auxiliary of Lehigh Valley Hospital Endowed Chair in Cancer.
With clinical expertise in melanoma, kidney cancer and immunotherapy, Dr. Nair’s focus is to provide the highest-quality cancer care, including standard and research treatments. He leads a variety of clinical trials at Lehigh Valley Health Network (LVHN) to provide leading-edge options to patients. He leads the high dose interleukin-2 program at LVHN for advanced melanoma and kidney cancer. Dr. Nair started the hematology/oncology fellowship at LVHN and served as the initial program director. He is a member of the American Board of Internal Medicine Medical Oncology Board.
Dr. Nair has been a site principal investigator in the National Cancer Institute (NCI) Cooperative Group Program for over 25 years and was the first Chair of the NCI Early Phase Central IRB. He has been a site principal investigator of over 40 T-cell checkpoint inhibitor trials at the Lehigh Valley Cancer Institute.
Dr. Nair received his medical degree from Jefferson Medical College. He completed his residency at Geisinger Medical Center and his fellowship at the University of Pittsburgh.
As of May 2018, Dr. Nair reported the following external relationships:
Funding for clinical trial support accrual, paid to Lehigh Valley Health Network, from the following companies:
- Bristol-Myers Squibb, for Phase II and Phase III Immuno-Oncology clinical trials.
- Merck, for a Phase III clinical trial for treatment of metastatic renal carcinoma.
- DNAtrix, for a Phase II clinical trial for treatment of glioblastoma.
Karen L. Reckamp, MD
Dr. Reckamp is board certified in Hematology and Medical Oncology and is Associate Professor of Medicine in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center in Duarte, California. The focus of her academic career includes developing and evaluating novel therapies for lung cancer as the Medical Director of the Thoracic Oncology Program at City of Hope. She serves as Chair of the Scientific Review Committee for the City of Hope Comprehensive Cancer Center.
Dr. Reckamp serves as a member of the American Board of Internal Medicine (ABIM) Medical Oncology Board. She also participates on the Scientific Advisory Board for the Free to Breathe foundation. She is a member of the American Society of Clinical Oncology (ASCO) Professional Development Committee. She was selected as a participant in the ASCO Leadership Development Program, which led a project on Maintenance of Certification in medical oncology. She previously participated in ASCO Test Material Development with instruction from ABIM.
Dr. Reckamp earned her medical degree from University of Chicago Pritzker School of Medicine and her master's degree in clinical investigation through the Specialized Training in Advanced Research from the Department of Biomathematics at University of California, Los Angeles (UCLA). Her postgraduate training includes an internship and residency in internal medicine at Barnes-Jewish Hospital in St. Louis, Missouri, and a hematology/oncology fellowship at the David Geffen School of Medicine at UCLA.
As of January 2017, Dr. Reckamp reported the following external relationships:
Clinical research, with funding for clinical trial expenses and clinical research staff, paid directly to City of Hope Cancer Center from the following companies:
- Acea, to support a Phase I trial of epidermal growth factor receptor in non-small cell lung cancer.
- Adaptimune, to support a trial on NY-ESO and MAGE-A10 CART cells.
- Clovis Oncology, to support Phase I/II trial of an investigational drug.
- Eisai, to support a Phase II trial of lenvatinib.
- Gilead Sciences, to support a Phase I trial of momelotinib and erlotinib.
- Genentech, to support a trial of atezolizumab.
- Pfizer, to support a Phase I trial of crizotinib and pembrolizumab.
Service on data and safety monitoring boards for the following companies, with compensation as listed:
- Amgen, overseeing a Phase III trial of Aranesp in non-small cell lung cancer, receiving reimbursement for travel expenses and honoraria.
- Astellas, overseeing a Phase lll trial of third-generation epidermal growth factor receptor in non-small cell lung cancer
Industry-supported continuing medical education supported by the following, with compensation for travel expenses and honoraria:
- Clinical Care Options, education on treatment for lung cancer.
Work funded by an educational grant from non-profit, paid to City of Hope, from the following company:
- STOP Cancer, Evaluation of mechanisms of resistance to therapy in small cell lung cancer, receiving funding for staff and project expenses.
Dr. Reckamp serves in significant roles with the following healthcare-related organization, receiving reimbursement or compensation as listed:
- American Society of Clinical Oncology, Quality of Care Committee, receiving travel reimbursement.
- Free to Breathe Scientific Advisory Board, without compensation.
- National Comprehensive Cancer Network, Lung Cancer Guideline Committee and Advisor for lung cancer educational material, receiving travel reimbursement and consulting fees.